Cytotoxicity-Inducing Therapeutic Agent

Patent No. EP3434767 (titled "Cytotoxicity-Inducing Therapeutic Agent") was filed by Chugai Seiyaku Kabushiki Kaisha on Nov 30, 2011. The application was issued on Jan 7, 2026.

Patent Summary

Cancer-fighting antibody that combines T-cell targeting with long blood life to avoid dangerous cytokine storms. A modified Fc domain binds T cells while a separate part targets cancer antigens, keeping T cells near tumors without triggering immune overreaction. Mutations in the Fc region reduce its ability to bind immune receptors, preventing unwanted inflammation. This design allows the drug to stay in the body longer than standard treatments, eliminating the need for continuous infusion pumps. The approach targets liver and lung cancers, offering a safer alternative to existing therapies that cause severe side effects at low doses.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
PAGEOct 7, 2026PAGE
VASILESCUOct 7, 2026VASILESCU
STRAWMANSep 29, 2026GREAVES BREWSTER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3434767

CHUGAI SEIYAKU KABUSHIKI KAISHA
Application Number
EP18192844A
Filing Date
Nov 30, 2011
Status
Granted And Under Opposition
Dec 5, 2025
Publication Date
Jan 7, 2026